Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME3 | Q16798 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.38 |
| ▸ | ME1 | P48163 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665419 | 0.84 | DRD2 (0.46) | ACHEHTR7CHRM4ME1MAPT | |
| SCHEMBL32665632 | 0.78 | CHRM4 (0.36) | TDP1ACHEHTR7CHRM4KDM4E | |
| SCHEMBL32665533 | 0.75 | TDP1 (0.45) | ME3TDP1PKMCHRM4DEGS1 | |
| SCHEMBL22434238 | 0.72 | MGLL (0.48) | HSP90AA1PKMMAPK1NPSR1MGLL | |
| SCHEMBL23550061 | 0.72 | MAPT (0.49) | ME3TDP1PKMNPSR1DEGS1 | |
| SCHEMBL24218198 | 0.71 | MGLL (0.46) | HSP90AA1PKMMAPK1NPSR1MGLL | |
| SCHEMBL32665021 | 0.71 | HTR1A (0.38) | ACHEHTR7CHRM4 | |
| SCHEMBL13279296 | 0.70 | GRIN2B (0.50) | — | |
| SCHEMBL32665425 | 0.69 | TDP1 (0.44) | ME3TDP1HSP90AA1PKMMAPK1 | |
| SCHEMBL15442277 | 0.69 | MAOB (0.53) | ME3MAPK1CHRM4DEGS1ME1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | ME3 1035/4885TDP1 3545/4885HSP90AA1 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.